Cargando…
Minimum clinically important difference analysis confirms the efficacy of IgPro10 in CIDP: the PRIMA trial
Autores principales: | Merkies, Ingemar S. J., Lawo, John‐Philip, Edelman, Jonathan M., De Bleecker, Jan L., Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Léger, Jean‐Marc |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wiley Periodicals, Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6084359/ https://www.ncbi.nlm.nih.gov/pubmed/28594116 http://dx.doi.org/10.1111/jns.12204 |
Ejemplares similares
-
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies
por: Merkies, Ingemar S.J., et al.
Publicado: (2019) -
Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)
por: Léger, Jean-Marc, et al.
Publicado: (2013) -
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study
por: van Schaik, Ivo N., et al.
Publicado: (2019) -
Switch from intravenous to subcutaneous immunoglobulin IgPro20 in CIDP patients: a prospective observational study under real-world conditions
por: Gingele, Stefan, et al.
Publicado: (2021) -
Deregulated Fcγ receptor expression in patients with CIDP
por: Quast, Isaak, et al.
Publicado: (2015)